Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical 5-fluorouracil with or without Cicaplast for actinic keratoses field therapy
ACTRN12624000911594Phase 3Not yet recruiting
- Sponsor
- The University of Queensland
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in actinic keratosis (AK) and squamous cell carcinoma (SCC) comparing Fluorouracil alone with Fluorouracil + Cicaplast Baume B5+ (2 arms). Primary endpoints: Number of topical 5% fluorouracil applications and Worst local skin reaction score. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
fluorouracilCicaplast Baume B5+
03
Conditions
actinic keratosis (AK)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on ACTRN12624000911594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000911594.